<DOC>
	<DOCNO>NCT02509026</DOCNO>
	<brief_summary>The purpose study study benefit risk etanercept withdrawal patient achieve significant clinical response .</brief_summary>
	<brief_title>Etanercept Withdrawal And Retreament Study In Subjects With Nr-ax SpA</brief_title>
	<detailed_description>This multcenter , open-label , three period study evaluate withdrawal retreatment etanercept subject nr-ax SpA achieve adequate response follow 24 week treatment .</detailed_description>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>diagnosis axial SpA duration symptom &gt; 3 month &lt; 5 year back pain less favorable response NSAIDs radiological sacroiliitis previous treatment TNF inhibitor , biologic , immunosuppressive</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>non-radiographic axial spondyloarthritis</keyword>
</DOC>